ACA
AZN icon

American Capital Advisory’s AstraZeneca AZN Stock Holding History

American Capital Advisory’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4K Sell
113
-5
-4% -$940 0.01% 297
2026
Q1 		$23.3K Buy
118
+52
+79% +$10K 0.01% 274
2025
Q4 		$12K Hold
66
– – 0.01% 315
2025
Q3 		$10.1K Buy
66
+20
+43% +$3.03K ﹤0.01% 311
2025
Q2 		$6.36K Hold
46
– – ﹤0.01% 320
2025
Q1 		$6.69K Buy
+46
New +$6.66K ﹤0.01% 320

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

American Capital Advisory's AZN Position: Q2 2026 in Review

American Capital Advisory reduced its AstraZeneca (AZN) stake by 4.2% in Q2 2026, selling an estimated $940 and leaving 113 shares worth $21.4K. The position accounts for 0.01% of the portfolio, ranked #297.

American Capital Advisory first reported a position in AZN in Q1 2025 and has held it in 6 quarters since. The position peaked at $23.3K in Q1 2026. 612 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • American Capital Advisory held 113 shares of AstraZeneca worth $21.4K as of Q2 2026.
  • American Capital Advisory sold 5 AstraZeneca shares in Q2 2026, an estimated $940.
  • AstraZeneca made up 0.01% of American Capital Advisory's portfolio in Q2 2026, its #297 holding.
  • American Capital Advisory first reported a position in AstraZeneca in Q1 2025 and has held it in 6 quarters since.
  • American Capital Advisory's AstraZeneca position peaked at $23.3K in Q1 2026.
  • 612 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.